Press releases

7th September 2022

STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer

Industry veteran to lead STORM as it transitions into a clinical-stage company with a pipeline of products targeting RNA modifying enzymes

3rd May 2022

STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme

STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies targeting RNA epigenetic mechanisms, today announces that it has been awarded a Biomedical Catalyst grant by Innovate UK to research and develop new drugs directed against a unique SARS-CoV2 protein utilizing STORM’s proprietary RNA epigenetic platform.

14th October 2021

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform

26th April 2021

STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML

Expected to be first RNA epigenetic drug programme globally to enter the clinic in 2022

8th March 2021

STORM Therapeutics Expands Scientific Advisory Board with the Appointment of Professor Tsutomu Suzuki

Dr. Tsutomu Suzuki is a professor at the department of chemistry and biotechnology in University of Tokyo, Japan.